{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:39:35Z","timestamp":1784770775984,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kite, a Gilead Company"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,9,7]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed\/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity.<\/jats:p>","DOI":"10.1136\/jitc-2020-001114","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T17:45:23Z","timestamp":1602870323000},"page":"e001114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02601313","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02601313","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Linda","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheree E","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Heimberger","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao-Pei","family":"Weathers","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianqing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Kite, A Gilead Company, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati V","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Kite, A Gilead Company, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Kite, A Gilead Company, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"2025100301082692000_8.2.e001114.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100301082692000_8.2.e001114.2","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"2025100301082692000_8.2.e001114.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100301082692000_8.2.e001114.4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100301082692000_8.2.e001114.5","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"2025100301082692000_8.2.e001114.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025100301082692000_8.2.e001114.7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"2025100301082692000_8.2.e001114.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396"},{"key":"2025100301082692000_8.2.e001114.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100301082692000_8.2.e001114.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100301082692000_8.2.e001114.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024"},{"key":"2025100301082692000_8.2.e001114.12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","article-title":"Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)","volume":"35","author":"Galon","year":"2017","journal-title":"JCO"},{"key":"2025100301082692000_8.2.e001114.13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V128.22.1227.1227","article-title":"Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1\/2 multicenter studies evaluating KTE-C19 in patients with relapsed\/refractory B-Precursor acute lymphoblastic leukemia (R\/R all)","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"2025100301082692000_8.2.e001114.14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.106542"},{"key":"2025100301082692000_8.2.e001114.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100301082692000_8.2.e001114.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"2025100301082692000_8.2.e001114.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"2025100301082692000_8.2.e001114.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"2025100301082692000_8.2.e001114.19","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000441965.15164.d6"},{"key":"2025100301082692000_8.2.e001114.20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"2025100301082692000_8.2.e001114.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1368"},{"key":"2025100301082692000_8.2.e001114.22","first-page":"P92","article-title":"Early biomarker correlates of severe neurologic events and cytokine release syndrome in ZUMA-1, a multicenter trial evaluating Axicabtagene Ciloleucel in refractory aggressive non-Hodgkin lymphoma","volume":"2017","author":"Locke","year":"2017","journal-title":"SITC"},{"key":"2025100301082692000_8.2.e001114.23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100301082692000_8.2.e001114.24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:08:36Z","timestamp":1759478916000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-001114"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001114","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}